These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33113415)

  • 21. Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy.
    Liu C; Nan Y; Xia Z; Gu K; Chen C; Dong X; Ju D; Zhao W
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127038. PubMed ID: 32088128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer.
    Du Q; Feng X; Wang Y; Xu X; Zhang Y; Qu X; Li Z; Bian J
    Eur J Med Chem; 2019 Nov; 182():111629. PubMed ID: 31445231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors.
    Pan L; Zheng Q; Chen Y; Yang R; Yang Y; Li Z; Meng X
    Eur J Med Chem; 2018 Sep; 157():423-436. PubMed ID: 30103191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
    Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
    Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors.
    Yang R; Chen Y; Pan L; Yang Y; Zheng Q; Hu Y; Wang Y; Zhang L; Sun Y; Li Z; Meng X
    Bioorg Med Chem; 2018 Sep; 26(17):4886-4897. PubMed ID: 30170925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: Optimization of potency and evaluation of anticancer potential.
    Jovanović M; Zhukovsky D; Podolski-Renić A; Žalubovskis R; Dar'in D; Sharoyko V; Tennikova T; Pešić M; Krasavin M
    Eur J Med Chem; 2020 Apr; 191():112119. PubMed ID: 32087464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents.
    Wu Y; Min X; Zhuang C; Li J; Yu Z; Dong G; Yao J; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Wei Y; Zhang H; Zhang W; Miao Z
    Eur J Med Chem; 2014 Jul; 82():545-51. PubMed ID: 24937186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
    Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
    Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory investigation of niacin derivatives on metalloenzyme indoleamine 2,3-dioxygenase 1 for its immunomodulatory function.
    Yan D; Xu J; Tan X
    Metallomics; 2021 Feb; 13(3):. PubMed ID: 33638642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
    Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
    Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity.
    Zheng X; Ma W; Sun R; Yin H; Lin F; Liu Y; Xu W; Zeng H
    Redox Biol; 2018 Apr; 14():237-249. PubMed ID: 28965082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
    Sari S; Tomek P; Leung E; Reynisson J
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
    Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
    Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy.
    He X; He G; Chu Z; Wu H; Wang J; Ge Y; Shen H; Zhang S; Shan J; Peng K; Wei Z; Zou Y; Xu Y; Zhu Q
    J Med Chem; 2021 Dec; 64(24):17950-17968. PubMed ID: 34854662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy.
    Wu Y; Zhang Y; Chen X; Hu Y; Dong G; Guo Y; Sheng C
    Eur J Med Chem; 2021 Mar; 213():113163. PubMed ID: 33482599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling.
    Zhu P; Qian J; Xu Z; Meng C; Liu J; Shan W; Zhu W; Wang Y; Yang Y; Zhang W; Zhang Y; Ling Y
    J Nat Prod; 2020 Oct; 83(10):3041-3049. PubMed ID: 33026807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening.
    Guo W; Yao S; Sun P; Yang TB; Tang CP; Zheng MY; Ye Y; Meng LH
    Acta Pharmacol Sin; 2020 Mar; 41(3):423-431. PubMed ID: 31197246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
    Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
    Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
    Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor.
    Wu Y; Duan Q; Zou Y; Zhu Q; Xu Y
    Bioorg Med Chem Lett; 2021 Nov; 52():128373. PubMed ID: 34560264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.